CDKN2A and cancer: In one of these clinical trials, a nested case-control study of stage I NSCLC patients with and without recurrent disease, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene, p16, and the H-cadherin gene, CDH13 was associated with recurrent cancer when the primary tumor and resected lymph nodes were evaluated by a multiplex methylation-specific PCR assay [91].